Cameron J. Koch

faculty photo
Professor of Radiation Biology in Radiation Oncology
Department: Radiation Oncology

Contact information
185 John Morgan Building
3620 Hamilton Walk
Philadelphia, PA 19104-6072
Office: 215-898-0073
Fax: 215-898-0090
University of Waterloo, Ontario, Canada, 1968.
University of Waterloo, Ontario, Canada, 1969.
University of Waterloo, Ontario, Canada, 1972.
Permanent link

Description of Research Expertise

Measurement of radioresistant hypoxic tumor cells in vivo using:
•immunohistochemistry and/or flow cytometry
•non-invasive imaging
•Quantification of tissue pO2
•Control and measurement of oxygen concentration and thiols
•Quantitative Fluorescence Microscopy
•Oxidative damage (primarily sulfydryl to disulfide) of DNA repair systems
•Effects of oxygen and oxygen radicals in biological or biochemical systems
•Development of fluorine-based PET imaging methods
•Automated chemical synthesis
•Mechanisms of action of radiation sensitizing and radiation protecting agents (survival or DNA damage)
•Models for competitive reactions of radiation modifying agents
•Metabolism of thiols and nitroheterocyclics (including cytotoxicity)
•Measurement of intracellular drug concentrations

Description of Itmat Expertise

Dr. Koch is primarily interested in invasive and non-invasive detection of cancer-therapy resistance, with specific interest in determining hypoxia in tissues.

Selected Publications

Koch CJ: A Two-Component Assay for Hypoxia Incorporating Long-Term Nitroreduction and Short-Term DNA-Damage Allows Differentiation of the Three Hypoxia Sub-types. Rad Res Page: 72-87, May 10 2018.

Koch CJ: Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [18F]EF5 PET/CT in head and neck cancer." in this issue of EJNMMI. European Journal of Nuclear Medicine and Molecular Imaging 45(2): 159-60, Feb 2018.

Makvandi M, Lin L, Effron SS, Lieberman BP, Anderson R-C, Xu K, Li S-H, Lee S, Hou C, Pryma DA, Koch CJ, Mach RH: PARP-1 expression quantified by [18F]FluorThanatrace: a biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother Radiopharm Feb 2017.

Ralph A. Pietrofesa, Anastasia Velalopoulou, Stacey L. Lehman, Evguenia Arguiri, Pantelis Solomides, Cameron J. Koch, Om P. Mishra, Constantinos Koumenis, Thomas J. Goodwin and Melpo Christofidou-Solomidou : Novel Double-Hit Model of Radiation and Hyperoxia-Induced Oxidative Cell Damage Relevant to Space Travel. Int J Mol Sci 17(6), Jun 2016.

Evans SM, Putt M, Yang XY, Lustig RA, Martinez-Lage M, Williams D, Desai A, Wolf R, Brem S, Koch CJ.: Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 127(2): 391-400, Apr 2016.

Lao Z, Kelly CJ, Yang XY, Jenkins WT, Toorens E, Ganguly T, Evans SM, Koch CJ.: Improved Methods to Generate Spheroid Cultures from Tumor Cells, Tumor Cells & Fibroblasts or Tumor-Fragments: Microenvironment, Microvesicles and MiRNA. PLoS One. 10(7): e0133895, Jul 24 2015.

Koch CJ, Evans SM: Pharmacokinetic and pharmacodynamic modifiers of EF5 uptake and binding. J Nucl Med. 56(4): 653, Apr 2015.

Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW.: Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry. Int J Cancer. 136(5), Mar 1 2015.

Koch CJ, Evans SM.: Optimizing hypoxia detection and treatment strategies. Semin Nucl Med. 45(2): 163-76, Mar 2015.

Koch CJ, Lustig RA, Yang XY, Jenkins WT, Wolf RL, Martinez-Lage M, Desai A, Williams D, Evans SM.: Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 7(6): 752-8, Dec 2014.

back to top
Last updated: 06/28/2018
The Trustees of the University of Pennsylvania